Skip to main content
SpringerLink
Log in

Gastrointestinal Involvement of Systemic Sclerosis

  • Chapter
  • First Online:
Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases

  • 465 Accesses

Abstract

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by microvascular abnormalities that result in fibrosis of the skin and other organs. Gastrointestinal (GI) manifestations are frequently observed in patients with SSc and occur in both diffuse cutaneous SSc and limited cutaneous SSc. The entire GI tract displays the pathological findings of SSc, including vasculopathy, smooth muscle atrophy, and excessive collagen deposition in the submucosa. As SSc progresses, the GI manifestations not only impair the quality of life by causing symptoms such as pain, nausea, vomiting, constipation, and fecal incontinence but are also related to poor prognosis. At present, the management of GI manifestations in patients with SSc is empirical and symptomatic. The goals of the treatment are the prevention of malnutrition and improvement of the quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Braun-Moscovici Y, Brun R, Braun M. Systemic sclerosis and the gastrointestinal tract-clinical approach. Rambam Maimonides Med J. 2016;7(4):e0031.

    Article  PubMed Central  Google Scholar 

  2. Turner R, Lipshutz W, Miller W, Rittenberg G, Schumacher HR, Cohen S. Esophageal dysfunction in collagen disease. Am J Med Sci. 1973;265(3):191–9.

    Article  CAS  PubMed  Google Scholar 

  3. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989;28(4):281–6.

    Article  CAS  PubMed  Google Scholar 

  4. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii36–9.

    Google Scholar 

  5. Tiev KP, Cabane J. Digestive tract involvement in systemic sclerosis. Autoimmun Rev. 2011;11(1):68–73.

    Article  PubMed  Google Scholar 

  6. Tian XP, Zhang X. Gastrointestinal complications of systemic sclerosis. World J Gastroenterol. 2013;19(41):7062–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, Saladini-Aponte C, et al. Gastrointestinal manifestations of systemic sclerosis. Rheumatology (Sunnyvale). 2018;8(1):235.

    Article  Google Scholar 

  8. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991;34(4):403–13.

    Article  CAS  PubMed  Google Scholar 

  9. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–44.

    Article  CAS  PubMed  Google Scholar 

  10. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994;37(9):1265–82.

    Article  CAS  PubMed  Google Scholar 

  11. Jaovisidha K, Csuka ME, Almagro UA, Soergel KH. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum. 2005;34(4):689–702.

    Article  PubMed  Google Scholar 

  12. Nishimagi E, Tochimoto A, Kawaguchi Y, Satoh T, Kuwana M, Takagi K, et al. Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol. 2007;34(10):2050–5.

    PubMed  Google Scholar 

  13. Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams RC Jr. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest. 1994;94(2):761–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology. 2002;123(4):1144–50.

    Article  CAS  PubMed  Google Scholar 

  15. Singh J, Mehendiratta V, Del Galdo F, Jimenez SA, Cohen S, DiMarino AJ, et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2009;297(6):G1206–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Singh J, Cohen S, Mehendiratta V, Mendoza F, Jimenez SA, Dimarino AJ, et al. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology. 2012;143(5):1308–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55(12):1697–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2012;32(1):165–8.

    Article  PubMed  Google Scholar 

  19. Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, et al. Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum. 2005;52(9):2882–8.

    Article  CAS  PubMed  Google Scholar 

  20. Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal involvement in systemic sclerosis: an update. J Clin Rheumatol. 2018;24(6):328–37.

    Article  PubMed  Google Scholar 

  21. Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179(5):408–13.

    Article  PubMed  Google Scholar 

  22. Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med. 1989;149(3):589–93.

    Article  CAS  PubMed  Google Scholar 

  23. Zhang XJ, Bonner A, Hudson M, Canadian Scleroderma Research Group, Baron M, Pope J. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol. 2013;40(6):850–8.

    Article  PubMed  Google Scholar 

  24. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010;40(3):241–9.

    Article  PubMed  Google Scholar 

  25. Marie I, Levesque H, Ducrotte P, Denis P, Hellot MF, Benichou J, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001;96(1):77–83.

    Article  CAS  PubMed  Google Scholar 

  26. Sridhar KR, Lange RC, Magyar L, Soykan I, McCallum RW. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med. 1998;132(6):541–6.

    Article  CAS  PubMed  Google Scholar 

  27. Franck-Larsson K, Hedenstrom H, Dahl R, Ronnblom A. Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol. 2003;32(6):348–55.

    Article  CAS  PubMed  Google Scholar 

  28. Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol. 2013;40(4):455–60.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Komiyama M, Fu K, Morimoto T, Konuma H, Yamagata T, Izumi Y, et al. A novel endoscopic ablation of gastric antral vascular ectasia. World J Gastrointest Endosc. 2010;2(8):298–300.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Marie I, Ducrotte P, Denis P, Hellot MF, Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis—a prospective manometric 5-yr follow-up. Rheumatology (Oxford). 2007;46(1):150–3.

    Article  CAS  Google Scholar 

  31. Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford). 2013;52(6):1095–100.

    Article  CAS  Google Scholar 

  32. Ponge T, Bruley des Varannes S. [Digestive involvement of scleroderma]. Rev Prat. 2002;52(17):1896–900.

    Google Scholar 

  33. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;23(6):691–712.

    Article  CAS  PubMed  Google Scholar 

  34. Gregersen H, Liao D, Pedersen J, Drewes AM. A new method for evaluation of intestinal muscle contraction properties: studies in normal subjects and in patients with systemic sclerosis. Neurogastroenterol Motil. 2007;19(1):11–9.

    Article  CAS  PubMed  Google Scholar 

  35. Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep. 2012;14(1):22–9.

    Article  PubMed  Google Scholar 

  36. Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Valenzuela A, Li S, Becker L, Fernandez-Becker N, Khanna D, Nguyen L, et al. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. Rheumatology (Oxford). 2016;55(4):654–8.

    Article  Google Scholar 

  38. Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007;25(3):237–40.

    Article  PubMed  Google Scholar 

  39. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–9.

    PubMed  Google Scholar 

  40. Kaneko M, Sasaki S, Teruya S, Ozaki K, Ishimaru K, Terai E, et al. Pneumatosis cystoides intestinalis in patients with systemic sclerosis: a case report and review of 39 Japanese cases. Case Rep Gastrointest Med. 2016;2016:2474515.

    PubMed  PubMed Central  Google Scholar 

  41. Kinjo M. Lurking in the wall: pneumatosis cystoides intestinalis with scleroderma. Am J Med. 2016;129(4):382–3.

    Article  PubMed  Google Scholar 

  42. Wu LL, Yang YS, Dou Y, Liu QS. A systematic analysis of pneumatosis cystoids intestinalis. World J Gastroenterol. 2013;19(30):4973–8.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Thoua NM, Schizas A, Forbes A, Denton CP, Emmanuel AV. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology (Oxford). 2011;50(9):1596–602.

    Article  Google Scholar 

  44. Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S. Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol. 1999;34(4):409–13.

    Article  CAS  PubMed  Google Scholar 

  45. Thoua NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am J Gastroenterol. 2012;107(4):597–603.

    Article  PubMed  Google Scholar 

  46. Malandrini A, Selvi E, Villanova M, Berti G, Sabadini L, Salvadori C, et al. Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol. 2000;27(5):1203–6.

    CAS  PubMed  Google Scholar 

  47. Compton R. Scleroderma with diverticulosis and colonic obstruction. Am J Surg. 1969;118(4):602–6.

    Article  CAS  PubMed  Google Scholar 

  48. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28; quiz 29.

    Article  PubMed  Google Scholar 

  49. Hostein J, Li V, Carpentier P, Fournet J. [Omeprazole: crucial progress in the treatment of esophagitis in progressive systemic scleroderma]. Gastroenterol Clin Biol. 1991;15(5):460–1.

    Google Scholar 

  50. Pakozdi A, Wilson H, Black CM, Denton CP. Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? Clin Exp Rheumatol. 2009;27(3 Suppl 54):5–8.

    CAS  PubMed  Google Scholar 

  51. Mercado U, Arroyo de Anda R, Avendano L, Araiza-Casillas R, Avendano-Reyes M. Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities. Clin Exp Rheumatol. 2005;23(5):685–8.

    CAS  PubMed  Google Scholar 

  52. Johnson DA, Drane WE, Curran J, Benjamin SB, Chobanian SJ, Karvelis K, et al. Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch Intern Med. 1987;147(9):1597–601.

    Article  CAS  PubMed  Google Scholar 

  53. Ramirez-Mata M, Ibanez G, Alarcon-Segovia D. Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS. Arthritis Rheum. 1977;20(1):30–4.

    Article  CAS  PubMed  Google Scholar 

  54. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37; quiz 8.

    Article  CAS  PubMed  Google Scholar 

  55. Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96(4):444–6.

    Article  PubMed  Google Scholar 

  56. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  57. McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–7.

    Article  CAS  PubMed  Google Scholar 

  58. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230–4.

    CAS  PubMed  Google Scholar 

  59. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322(15):1028–31.

    Article  CAS  PubMed  Google Scholar 

  60. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002;97(1):194–7.

    Article  CAS  PubMed  Google Scholar 

  61. Takahashi T, Endo S, Nakajima K, Souma Y, Nishida T. Effect of rikkunshito, a chinese herbal medicine, on stasis in patients after pylorus-preserving gastrectomy. World J Surg. 2009;33(2):296–302.

    Article  PubMed  Google Scholar 

  62. Ingraham KM, O'Brien MS, Shenin M, Derk CT, Steen VD. Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors. J Rheumatol. 2010;37(3):603–7.

    Article  PubMed  Google Scholar 

  63. Marie I, Ducrotte P, Antonietti M, Herve S, Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther. 2008;28(4):412–21.

    Article  CAS  PubMed  Google Scholar 

  64. Nagaraja V, McMahan ZH, Getzug T, Khanna D. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol. 2015;1(1):82–105.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13(2):111–6.

    CAS  PubMed  Google Scholar 

  66. Frech TM, Khanna D, Maranian P, Frech EJ, Sawitzke AD, Murtaugh MA. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S22–5.

    PubMed  Google Scholar 

  67. Rees WD, Leigh RJ, Christofides ND, Bloom SR, Turnberg LA. Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology. 1982;83(3):575–80.

    CAS  PubMed  Google Scholar 

  68. Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007;13(3):119–23.

    Article  PubMed  Google Scholar 

  69. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995;40(9):1892–901.

    Article  CAS  PubMed  Google Scholar 

  70. Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002;51(6):881–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Hiroshi Watanabe

Authors
  1. Hiroshi Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Watanabe .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Hiromasa Ohira

  2. Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Kiyoshi Migita

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Watanabe, H. (2019). Gastrointestinal Involvement of Systemic Sclerosis. In: Ohira, H., Migita, K. (eds) Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-13-6524-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-6524-9_8

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-6523-2

  • Online ISBN: 978-981-13-6524-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation